Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724045 | 0.91 | TACR1 (0.40) | TACR1TACR3CRHR1HCRTR1HCRTR2 | |
| SCHEMBL5724385 | 0.90 | TACR1 (0.41) | TACR1TACR3CRHR1HCRTR1HCRTR2 | |
| SCHEMBL5724293 | 0.88 | CRHR1 (0.37) | TACR1TACR3CRHR1ADORA2AADORA1 | |
| SCHEMBL5724284 | 0.82 | TACR1 (0.40) | TACR1TACR3CRHR1HCRTR1HCRTR2 | |
| SCHEMBL5724157 | 0.79 | CRHR1 (0.40) | CRHR1ADORA2AADORA1 | |
| SCHEMBL5724420 | 0.78 | CRHR1 (0.48) | TACR1TACR3CRHR1ADORA2AADORA1 | |
| SCHEMBL5724525 | 0.78 | CRHR1 (0.41) | TACR1TACR3CRHR1HCRTR1HCRTR2 | |
| SCHEMBL5724400 | 0.72 | TACR1 (0.36) | TACR1TACR3CRHR1ADORA2AADORA1 | |
| SCHEMBL5724194 | 0.71 | CRHR1 (0.40) | CRHR1ADORA2AADORA1 | |
| SCHEMBL5724470 | 0.69 | CRHR1 (0.35) | CRHR1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620428-A1 | SUBSTITUTED PYRIMIDINONES AND PYRIMIDINTHIONES AS CRF ANTAGONISTS | Pharmacia & Upjohn Company LLC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050143403-A1 | Substituted pyrimidinones and pyrimidinthiones | PFIZER INC | 2005-06-30 | — | — | US | claimed |
| WO-2004094408-A1 | SUBSTITUTED PYRIMIDINONES AND PYRIMIDINTHIONES AS CRF ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20050143403-A1 | Substituted pyrimidinones and pyrimidinthiones | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143403-A1 | Substituted pyrimidinones and pyrimidinthiones | CRHR1, CRH, CRHR2 | TACR1 17/4885TACR3 153/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.